Look back at pharma news to Mar 3
The introduction in the USA of legislation to encourage the importation of cheaper prescription drugs from Canada and elsewhere could have serious impact on drugmakers. Last week also saw focus on the decline of the hepatitis C market as a result of the success of new drugs to treat the condition. Additionally, there was excitement around potential new drugs from La Jolla, Kite Pharma and Chi-Med.
Vulnerability of Valeant to cheaper drug imports
US Senators Sanders and Booker proposed a new bill to allow imports of cheaper drugs. They could potentially get President Trump on board. The Senate previously recommended importing cheaper drugs to combat price gougers like Valeant Pharmaceuticals International, wrote blogger “Shock Exchange” on Seeking Alpha, noting that cheaper drugs could hasten the firm's demise amid nearly $30 billion in debt.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze